Evolus, Inc. (NASDAQ:EOLS - Get Free Report) shares shot up 15.3% on Thursday . The company traded as high as $14.85 and last traded at $16.44. 203,784 shares were traded during trading, a decline of 77% from the average session volume of 868,460 shares. The stock had previously closed at $14.26.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Needham & Company LLC reissued a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Tuesday, January 21st. Barclays raised their target price on Evolus from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Monday, January 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Evolus in a report on Friday.
Read Our Latest Stock Report on EOLS
Evolus Price Performance
The company has a market cap of $933.34 million, a price-to-earnings ratio of -16.20 and a beta of 1.33. The company has a fifty day moving average price of $12.13 and a two-hundred day moving average price of $14.00. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.
Institutional Trading of Evolus
Several institutional investors have recently modified their holdings of EOLS. Creative Planning grew its holdings in shares of Evolus by 23.7% during the 3rd quarter. Creative Planning now owns 15,451 shares of the company's stock worth $250,000 after purchasing an additional 2,963 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Evolus by 0.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company's stock worth $15,480,000 after purchasing an additional 8,452 shares in the last quarter. Semanteon Capital Management LP acquired a new stake in shares of Evolus during the 3rd quarter worth approximately $912,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Evolus by 65.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company's stock worth $197,000 after purchasing an additional 4,780 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its holdings in shares of Evolus by 6.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company's stock worth $14,659,000 after purchasing an additional 53,605 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
